Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.55 |
| ▸ | HTR3A | P46098 | 6/20 | 0.52 |
| ▸ | HTR4 | Q13639 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503780 | 0.88 | PARP1 (0.56) | PARP1HTR3AHTR4KDM4EPKM | |
| SCHEMBL4495617 | 0.87 | PARP1 (0.56) | PARP1HTR3AHTR4KDM4EPKM | |
| SCHEMBL4495524 | 0.83 | PARP1 (0.51) | PARP1HTR3AHTR4KDM4EPKM | |
| SCHEMBL828769 | 0.81 | HTR3A (0.62) | PARP1HTR3AHTR4KDM4EPKM | |
| SCHEMBL4496187 | 0.80 | PARP1 (0.49) | PARP1KDM4EPKMPRMT5 | |
| SCHEMBL828868 | 0.80 | HTR3A (0.76) | PARP1HTR3AHTR4KDM4EPKM | |
| SCHEMBL4502102 | 0.79 | KDM4E (0.55) | PARP1KDM4EPKMPRMT5 | |
| SCHEMBL1201970 | 0.78 | HTR3A (0.49) | PARP1HTR3AHTR4KDM4EMEN1 | |
| SCHEMBL1201372 | 0.77 | PARP1 (0.48) | PARP1HTR3AHTR4KDM4EPKM | |
| SCHEMBL828678 | 0.77 | HTR4 (0.67) | PARP1HTR3AHTR4KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | PARP1 972/4885HTR3A 46/4885HTR4 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.